人福医药：HWS117注射液获临床试验批准

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary has received approval for clinical trials of HWS117 injection, a new long-acting follicle-stimulating hormone (FSH) drug aimed at improving fertility treatments [1] Group 1: Product Development - HWS117 injection is intended for controlled ovarian stimulation in assisted reproduction, promoting the development of multiple follicles [1] - The drug aims to extend the half-life of FSH in the body, addressing clinical needs for reduced injection frequency and improved treatment adherence [1] - Cumulative R&D investment in the project has reached approximately 36 million RMB [1]